These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 31816446)

  • 1. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
    Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
    Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
    N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Kowalski K; Sandborn WJ; Feagan B
    Clin Ther; 2022 Oct; 44(10):1336-1355. PubMed ID: 36150926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Hu C; Chen Y; Miao X; Adedokun OJ; Xu Z; Sharma A; Zhou H
    J Clin Pharmacol; 2020 Jul; 60(7):889-902. PubMed ID: 32026499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
    Abreu MT; Rowbotham DS; Danese S; Sandborn WJ; Miao Y; Zhang H; Tikhonov I; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Arasaradnam RP; Afif W; Peyrin-Biroulet L; Sands BE; Marano C
    J Crohns Colitis; 2022 Aug; 16(8):1222-1234. PubMed ID: 35239968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
    Sandborn WJ; Feagan BG; Danese S; O'Brien CD; Ott E; Marano C; Baker T; Zhou Y; Volger S; Tikhonov I; Gasink C; Sands BE; Ghosh S
    Inflamm Bowel Dis; 2021 Jun; 27(7):994-1007. PubMed ID: 32964215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.
    Vasudevan A; Tharayil V; Raffals LH; Bruining DH; Becker M; Murad MH; Loftus EV
    Inflamm Bowel Dis; 2024 Apr; 30(4):660-670. PubMed ID: 37071852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
    Li K; Friedman JR; Chan D; Pollack P; Yang F; Jacobstein D; Brodmerkel C; Gasink C; Feagan BG; Sandborn WJ; Rutgeerts P; De Hertogh G
    Gastroenterology; 2019 Oct; 157(4):1019-1031.e7. PubMed ID: 31279870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
    Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
    Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
    Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
    N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.